What is HC Wainwright’s Estimate for TLX FY2025 Earnings?

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Research analysts at HC Wainwright lowered their FY2025 earnings per share estimates for Telix Pharmaceuticals in a research note issued to investors on Monday, December 22nd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of $0.19 for the year, down from their previous estimate of $0.28. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. HC Wainwright also issued estimates for Telix Pharmaceuticals’ FY2026 earnings at $0.59 EPS.

Several other analysts have also recently commented on TLX. Royal Bank Of Canada began coverage on Telix Pharmaceuticals in a report on Monday, December 15th. They issued a “hold” rating for the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. UBS Group lowered their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

TLX stock opened at $8.10 on Wednesday. Telix Pharmaceuticals has a 52-week low of $7.72 and a 52-week high of $30.36. The stock’s fifty day simple moving average is $9.61 and its 200-day simple moving average is $11.66.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in Telix Pharmaceuticals during the third quarter worth approximately $1,883,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter valued at $1,097,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter valued at $1,225,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals during the 3rd quarter worth $243,000.

Key Stores Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $20 price target on TLX, which supports longer‑term upside sentiment despite other negative headlines. HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)
• Neutral Sentiment: Reported short‑interest data for December appears noisy/erroneous (claims of a big increase but shows 0 shares), so there is no clear evidence yet of a coordinated short squeeze or large new short position to explain price moves.
• Negative Sentiment: Hagens Berman is driving a major class‑action push alleging dual regulatory failures at Telix (including an SEC subpoena and an FDA CRL tied to CMC/supply‑chain/manufacturing), raising legal and operational uncertainty that likely weighs on the stock. TLX CLASS ACTION DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures
• Negative Sentiment: Multiple plaintiff firms (Bronstein, Faruqi & Faruqi, Glancy Prongay & Murray, Rosen, etc.) have filed or are soliciting lead plaintiffs in securities suits covering Feb. 21–Aug. 28, 2025 — increased litigation activity raises potential settlement risk and investor uncertainty. Bronstein, Gewirtz & Grossman LLC Urges Telix Pharmaceuticals Limited Investors to Act: Class Action Filed
• Negative Sentiment: HC Wainwright trimmed FY2025 and FY2026 EPS estimates materially (FY26 cut from $0.92 to $0.59; FY25 from $0.28 to $0.19) — weaker earnings outlook increases short‑to‑medium term valuation risk even though the firm kept a Buy rating. Telix Pharmaceuticals analyst note (MarketBeat summary of HC Wainwright estimate cuts)

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.